Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton’s Tyrosine Kinase Inhibitors
Meghan C. Thompson, Anthony R. Mato
Topics & Concepts
IbrutinibDiscontinuationChronic lymphocytic leukemiaMedicineVenetoclaxBruton's tyrosine kinaseTyrosine kinaseAdverse effectOncologyInternal medicineLeukemiaPharmacologyReceptorChronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune DisordersChronic Myeloid Leukemia Treatments